ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
AbCellera Biologics Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research fees | $28.53M | $31.26M | $27.21M | $24.29M | $21.76M | $20.58M | $26.28M | $30.26M | $30.38M | $34.76M | $35.56M | $38.24M | 43.1% | +31.1% |
| Royalty revenue | – | – | – | – | – | – | – | – | – | – | $0 | $9.46M | – | – |
| Licensing and royalty revenue | – | – | $46.92M | $11.03M | $11.11M | $1.04M | $1.05M | $953.00K | $921.00K | $777.00K | $969.00K | $949.00K | – | – |
| Milestone payments | – | – | $1.00M | – | – | – | $1.50M | $1.75M | $1.75M | $250.00K | $1.50M | $1.75M | – | – |
By region
From the segment and revenue-disaggregation notes of AbCellera Biologics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.